OrthoPediatrics Corp. (NASDAQ: KIDS) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | - | Shs Outstand | 25.68M | Perf Week | 5.24% |
| Market Cap | 536.30M | Forward P/E | - | EPS next Y | -0.81 | Insider Trans | -0.17% | Shs Float | 17.08M | Perf Month | 2.10% |
| Enterprise Value | 591.30M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 5.16% | Perf Quarter | 32.32% |
| Income | -40.00M | P/S | 2.21 | EPS this Y | 29.76% | Inst Trans | - | Short Ratio | 5.39 | Perf Half Y | 20.76% |
| Sales | 243.00M | P/B | 1.58 | EPS next Y | 31.54% | ROA | -7.90% | Short Interest | 881.26K | Perf YTD | 17.57% |
| Book/sh | 13.20 | P/C | 10.52 | EPS next 5Y | - | ROE | -11.42% | 52W High | 22.80 -8.42% | Perf Year | 2.40% |
| Cash/sh | 1.99 | P/FCF | - | EPS past 3/5Y | - | ROIC | -6.41% | 52W Low | 14.42 44.80% | Perf 3Y | -49.89% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 24.60% 27.15% | Gross Margin | 73.07% | Volatility | 4.66% 5.36% | Perf 5Y | -65.82% |
| Dividend TTM | - | EV/Sales | 2.43 | EPS Y/Y TTM | -2.44% | Oper. Margin | -12.07% | ATR (14) | 1.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.37 | Sales Y/Y TTM | 18.54% | Profit Margin | -16.31% | RSI (14) | 62.15 | Recom | 2.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.21 | EPS Q/Q | -7.69% | SMA20 | 5.14% | Beta | 0.97 | Target Price | 21.00 |
| Payout | 0.00% | Debt/Eq | 0.29 | Sales Q/Q | 13.46% | SMA50 | 9.70% | Rel Volume | 1.72 | Prev Close | 20.87 |
| Employees | 602 | LT Debt/Eq | 0.29 | Earnings | Oct 27 | SMA200 | 17.83% | Avg Volume | 156.67K | Price | 20.88 |
| IPO Date | Oct 13, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.74% 1.85% | Net Debt/EBITDA | -13.89 | Volume | 268,887 | Change | 0.05% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-01-26 | Reiterated | Truist Financial | Hold | $20 → $17 |
| Apr-24-26 | Reiterated | Canaccord Genuity | $24 → $25 | |
| Dec-10-25 | Reiterated | Canaccord Genuity | $24 | |
| Oct-29-25 | Reiterated | Needham | Buy | $42 → $26 |
| Oct-10-25 | Reiterated | Truist Financial | Hold | $22 → $18 |
| Oct-10-25 | Reiterated | Stifel Nicolaus | Buy | $32 → $20 |
| Oct-10-25 | Reiterated | JMP Securities | Market Outperform | $35 → $25 |
| Oct-10-25 | Reiterated | Lake Street | Buy | $34 |
| Oct-10-25 | Reiterated | Piper Sandler | Overweight | $44 → $22 |
| Oct-10-25 | Reiterated | BTIG | Buy | $44 → $23 |
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 243 | 236 | 205 | 149 | 122 | 98 | 71 | 73 | 58 | |
| Cost of Goods Sold Incl. D&A | 65 | 64 | 56 | 37 | 32 | 25 | 16 | 18 | 15 | |
| Gross Profit | 177 | 173 | 149 | 111 | 91 | 73 | 55 | 55 | 43 | |
| Selling, General and Administrative Excl. Other | 195 | 193 | 167 | 126 | 104 | 86 | 70 | 58 | 48 | |
| Research and Development | 8 | 9 | 11 | 11 | 8 | 6 | 5 | 6 | 5 | |
| Other Operating Expense | 5 | 0 | 0 | 1 | 4 | -1 | 7 | 0 | -1 | |
| Operating Income | -30 | -29 | -30 | -27 | -25 | -18 | -27 | -9 | -10 | |
| Interest Expense | 7 | 6 | 3 | 0 | 2 | 2 | 3 | 4 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | -4 | -10 | 5 | 24 | 3 | -3 | 0 | 0 | |
| Net Income Before Taxes | -40 | -39 | -42 | -21 | -4 | -17 | -34 | -13 | -12 | |
| Income Taxes | 0 | 0 | -4 | 0 | -5 | -1 | -1 | 0 | 0 | |
| Consolidated Net Income | -40 | -40 | -38 | -21 | 1 | -16 | -33 | -14 | -12 | |
| Net Income From Continuing Operations | -40 | -40 | -38 | -21 | 1 | -16 | -33 | -13 | -12 | |
| Net Income | -40 | -40 | -38 | -21 | 1 | -16 | -33 | -14 | -12 | |
| EPS (Recurring) | -1.68 | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -1.18 | -0.96 | |
| EPS (Basic, Before Extraordinaries) | -1.68 | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -1.18 | -0.96 | |
| EPS (Diluted) | -1.68 | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -1.18 | -0.96 | |
| EBITDA | -7 | -12 | -20 | -8 | -9 | -7 | -22 | -5 | -7 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | 673.39 | — | — | — | — | |
| Price To Sales Ratio | 2.06 | 1.73 | 2.60 | 5.02 | 6.84 | 11.61 | 10.46 | 9.66 | 7.82 | |
| Gross Margin | 72.84 | 73.31 | 72.68 | 74.50 | 74.59 | 74.49 | 77.46 | 75.34 | 74.14 | |
| Operating Margin | -12.35 | -12.29 | -14.63 | -18.12 | -20.49 | -18.37 | -38.03 | -12.33 | -17.24 | |
| Net Margin | -16.46 | -16.95 | -18.54 | -14.09 | 0.82 | -16.33 | -46.48 | -19.18 | -20.69 | |
| Shares Outstanding | 24 | 23 | 23 | 23 | 21 | 19 | 18 | 15 | 13 | |
| Market Capitalization | 501 | 408 | 533 | 748 | 834 | 1,137 | 743 | 705 | 453 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Odle Gregory A | President of Scoliosis | Mar 16 '26 | Sale | 17.25 | 8,433 | 145,469 | 187,735 | Mar 17 |
| Hite Fred | COO and CFO | Mar 16 '26 | Sale | 17.25 | 12,993 | 224,129 | 277,477 | Mar 17 |
| Gerritzen Daniel J | General Counsel and Secretary | Mar 16 '26 | Sale | 17.25 | 8,614 | 148,592 | 149,533 | Mar 17 |
| Hauser Joseph W | Pres. Trauma & Def. Correction | Mar 16 '26 | Sale | 17.25 | 8,596 | 148,281 | 194,767 | Mar 17 |
| Bailey David R | President and CEO | Mar 16 '26 | Sale | 17.25 | 19,535 | 336,979 | 298,020 | Mar 17 |
| Hite Fred | COO and CFO | Aug 21 '25 | Buy | 19.41 | 5,076 | 98,525 | 213,065 | Aug 25 |
| Gerritzen Daniel J | General Counsel and Secretary | Mar 18 '25 | Sale | 24.86 | 5,310 | 132,007 | 110,767 | Mar 18 |
| Bailey David R | President and CEO | Mar 18 '25 | Sale | 24.86 | 6,620 | 164,573 | 319,155 | Mar 18 |
| Hite Fred | COO and CFO | Mar 18 '25 | Sale | 24.86 | 6,443 | 160,173 | 207,989 | Mar 18 |
| Odle Gregory A | President of Scoliosis | Mar 18 '25 | Sale | 24.86 | 5,359 | 133,225 | 148,788 | Mar 18 |
| Hauser Joseph W | Pres. Trauma & Def. Correction | Mar 18 '25 | Sale | 24.86 | 5,300 | 131,758 | 137,663 | Mar 18 |
| Gerritzen Daniel J | General Counsel and Secretary | Aug 21 '24 | Sale | 29.30 | 10,000 | 293,000 | 77,304 | Aug 22 |
| Hite Fred | COO and CFO | Mar 11 '24 | Sale | 27.59 | 3,195 | 88,150 | 94,072 | Mar 12 |
| Bailey David R | President and CEO | Mar 11 '24 | Sale | 27.59 | 3,213 | 88,647 | 139,384 | Mar 12 |
| Gerritzen Daniel J | General Counsel and Secretary | Mar 11 '24 | Sale | 27.59 | 2,741 | 75,624 | 52,403 | Mar 12 |